Cargando…
Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics
Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179382/ https://www.ncbi.nlm.nih.gov/pubmed/37176743 http://dx.doi.org/10.3390/jcm12093303 |
_version_ | 1785041084724805632 |
---|---|
author | Rossi, Mariateresa Damiani, Caterina Arisi, Mariachiara Tomasi, Cesare Tonon, Francesco Venturini, Marina Calzavara-Pinton, Piergiacomo |
author_facet | Rossi, Mariateresa Damiani, Caterina Arisi, Mariachiara Tomasi, Cesare Tonon, Francesco Venturini, Marina Calzavara-Pinton, Piergiacomo |
author_sort | Rossi, Mariateresa |
collection | PubMed |
description | Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.90 with UVA1 and 13.70 with NB-UVB. The rates of patients achieving an IGA score of 0/1 persistent for at least 6 months were 33% with UVA1 and 28% with NB-UVB, and the rates with an EASI90 improvement were 10.9% with UVA1 and 11.0% with NB-UVB. The cut-off baseline EASI values for a good probability to achieve a 0/1 IGA were 24.4 with UVA1 and 24.7 with NB-UVB. A 0/1 IGA persistent for at least 6 months was more likely to be achieved by patients with a history of flares interspersed with periods of mild or no disease. From 2018, we only enrolled patients with the above-mentioned characteristics. The number of treated patients was lower, but the final EASI score, the rate of patients achieving IGA 0/1 persistent for at least 6 months, and EASI90 were significantly higher. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission. |
format | Online Article Text |
id | pubmed-10179382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101793822023-05-13 Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics Rossi, Mariateresa Damiani, Caterina Arisi, Mariachiara Tomasi, Cesare Tonon, Francesco Venturini, Marina Calzavara-Pinton, Piergiacomo J Clin Med Article Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s, but the clinical indications for their use “at the age of biologics” remain to be assessed. From 2013 to 2017, 145 patients underwent a first treatment cycle with phototherapy. They achieved a median final EASI score of 9.90 with UVA1 and 13.70 with NB-UVB. The rates of patients achieving an IGA score of 0/1 persistent for at least 6 months were 33% with UVA1 and 28% with NB-UVB, and the rates with an EASI90 improvement were 10.9% with UVA1 and 11.0% with NB-UVB. The cut-off baseline EASI values for a good probability to achieve a 0/1 IGA were 24.4 with UVA1 and 24.7 with NB-UVB. A 0/1 IGA persistent for at least 6 months was more likely to be achieved by patients with a history of flares interspersed with periods of mild or no disease. From 2018, we only enrolled patients with the above-mentioned characteristics. The number of treated patients was lower, but the final EASI score, the rate of patients achieving IGA 0/1 persistent for at least 6 months, and EASI90 were significantly higher. Medium-dose UVA1 and NB-UVB phototherapies remain useful for the treatment of AD patients with a baseline EASI score lower than 24.4 and 24.7, respectively, and a medical history of flares followed by prolonged periods of complete or near-complete remission. MDPI 2023-05-05 /pmc/articles/PMC10179382/ /pubmed/37176743 http://dx.doi.org/10.3390/jcm12093303 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rossi, Mariateresa Damiani, Caterina Arisi, Mariachiara Tomasi, Cesare Tonon, Francesco Venturini, Marina Calzavara-Pinton, Piergiacomo Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title | Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title_full | Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title_fullStr | Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title_full_unstemmed | Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title_short | Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis for Whom Narrow-Band UVB (NB-UVB) and Medium-Dose UVA1 Phototherapies Are Still Valuable Treatment Options at the Age of Biologics |
title_sort | definition of the clinical characteristics of patients with moderate and severe atopic dermatitis for whom narrow-band uvb (nb-uvb) and medium-dose uva1 phototherapies are still valuable treatment options at the age of biologics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179382/ https://www.ncbi.nlm.nih.gov/pubmed/37176743 http://dx.doi.org/10.3390/jcm12093303 |
work_keys_str_mv | AT rossimariateresa definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT damianicaterina definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT arisimariachiara definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT tomasicesare definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT tononfrancesco definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT venturinimarina definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics AT calzavarapintonpiergiacomo definitionoftheclinicalcharacteristicsofpatientswithmoderateandsevereatopicdermatitisforwhomnarrowbanduvbnbuvbandmediumdoseuva1phototherapiesarestillvaluabletreatmentoptionsattheageofbiologics |